The role of dopamine in reward and pleasure behaviour - Review of data from preclinical research

Acta Psychiatrica Scandinavica, Supplement

Volumn 111, Issue 427, 2005, Pages 14-21

  Bressan, Rodrigo A ^a   Crippa, J A ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anhedonia; Depression; Dopamine; Dysphoria; Reward system; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; DOPAMINE RECEPTOR; TYROSINE;

ANHEDONIA; ANIMAL BEHAVIOR; APATHY; BRAIN FUNCTION; BRAIN REGION; CLINICAL PATHWAY; COMPLEX FORMATION; DEPRESSION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC CORTEX; MOTIVATION; NERVE CELL NETWORK; NEUROANATOMY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PSYCHOSIS; REVIEW; REWARD; SCHIZOPHRENIA; SIDE EFFECT; AFFECT; BRAIN; METABOLISM; PSYCHOANALYTIC THEORY;

AFFECT; BRAIN; DOPAMINE; HUMANS; PLEASURE-PAIN PRINCIPLE; RECEPTORS, DOPAMINE; REWARD; TYROSINE;

EID: 20344394087     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2005.00540.x     Document Type: Review

References (62)

1. CARLSSON A, LINDQVIST M, MAGNUSSON T, WALDECK B. On the presence of 3-hydroxytyramine in brain. Science 1958;127:471.
2. CARLSSON A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Ver 1959;11:49-93.
3. WISE RA, SPINDLER J, DEWIT H, GERBERG GJ. Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food. Science 1978;201:262-264.
4. VORUGANTI L, AWAD AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 2004;171:121-132.
5. PEROUTKA SJ, SYNDER SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980;137:1518-1522.
6. SNYDER SH. Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry 1972;27:169-179.
7. ANGRIST BM, SHOPSIN B, GERSHON S. Comparative psychotomimetic effects of stereoisomers of amphetamine. Nature 1971;234:152-153.
8. CARLSSON A. Does dopamine play a role in schizophrenia? Psychol Med 1977;7:583-597.
9. CARLSSON M, CARLSSON A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 1990;16:425-432.
10. HIETALA J, SYVALAHTI E, VUORIO K et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346:1130-1131.
11. LARUELLE M, ABI-DARGHAM A, VAN DYCK CH et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235-9240.
12. ABI-DARGHAM A, RODENHISER J, PRINTZ D et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-8109.
13. KAPUR S, MAMO D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1081-1090.
14. KAPUR S, ZIPURSKY RB, JONES C, REMINGTON GJ, HOULE S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
15. NÖRDSTROM AL, FARDE L, WIESEL FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235.
16. CARLSSON A, WALDECK B. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol Scand 1958;44:293-298.
17. GRACE AA. Dopamine. In: DAVIS KL, CHARNEY D, COYLE JT, NEMEROFF C, eds. Neuropsychopharmacology - the fifth generation of progress. Philadelphia, PA: Lippincott Williams and Wilkins, 2002:119-132.
18. ELSWORTH JD, ROTH RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1997;144:4-9.
19. CHIODO LA, FREEMAN AS, BUNNEY BS. Dopamine auto receptor signal transduction and regulation. In: BORRONI E, KUPFER DJ, eds. Psychopharmacology: the forth generation of progress. New York: Raven Press Ltd, 1995:221-226.
20. CIVELLI O. Molecular biology of the dopamine receptor subtypes. In: BORRONI E, KUPFER DJ, eds. Psychopharmacology: the forth generation of progress. New York: Raven Press Ltd, 1995:155-161.
21. GRACE AA, BUNNEY BS. Electrophysiological properties of midbrain dopamine neurons. In: BORRONI E, KUPFER DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press Ltd, 1995:163-177.
22. BANNON MJ, SACCHETTI P, GRANNEMAN JG. The dopamine transporter: potential involvement in neuropsychiatric disorders. In: BORRONI E, KUPFER DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press Ltd, 1995:179-188.
23. KEBABIAN JW, CALNE DB. Multiple receptors for dopamine. Nature 1979;277:93-96.
24. CREESE I, FRASER CM. Dopamine receptors. New York: John Wiley and Sons Inc, 1987.
25. CIVELLI O, BUNZOW JR, GRANDY DK. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1992;32:281-307.
26. 1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A 1991;88:3772-3776.
27. SPANO PF, GOVONI S, TRABUCCHI M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol 1978;19:155-165.
28. SEEMAN P. Dopamine receptors: clinical correlates. In: BORRONI E, KUPFER DJ, eds. Psychopharmacology: the forth generation of progress. New York: Raven Press Ltd, 1995:295-302.
29. BUCKLAND PR, O'DONOVAN MC, MCGUFFIN P. Both splicing variants of the dopamine D2 receptor mRNA are upregulated by antipsychotic drugs. Neurosci Lett 1993;150:25-28.
30. GARDNER B, HALL DA, STRANGE PG. Pharmacological analysis of dopamine stimulation of [35S]-GTPgS binding via human D2short and D21ong dopamine receptors expressed in recombinant cells. Br J Pharmacol 1996;118:1544-1550.
31. CASTRO SW, STRANGE PG. Differences in the ligand binding properties of the short and long versions of the D2 dopamine receptor. J Neurochem 1993;60:372-375.
32. ITOKAWA M, TORU M, ITO K et al. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 1996;49:560-566.
33. MOAL ML. Mesocorticolimbic dopaminergic neurons functional and regulatory roles. In: BORRONI E, KUPFER DJ, eds. Psychopharmacology: the forth generation of progress. New York: Raven Press Ltd, 1995:283-294.
34. GRACE AA, BUNNEY BS. The control of firing pattern in nigraldopamine neurons: burst firing. J Neurosci 1984;4:2877-2890.
35. ERHARDT S, NISSBRANDT H, ENGBERG G. Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm 1999;106:383-394.
36. GRILLNER P, BERRETTA N, BERNARDI G et al. Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. Neuroscience 2000;96:299-307.
37. OLDS J, MILNER P. Positive reinforcement produced by electrical stimulation of septal area and other regions of the rat brain. J Comp Physiol Psychol 1954;47:419-427.
38. KALIVAS PW. Neurocircuitry of addiction. In: DAVIS KL, CHARNEY D, COYLE JT, NEMEROFF C, eds. Neuropsychopharmacology - the fifth generation of progress. Philadelphia, PA: Lippincott Williams and Wilkins, 2002:1357-1366.
39. WISE RA, ROMPRÉ PP. Brain dopamine and reward. Ann Rev Psychol 1989;40:191-225.
40. DI CHIARA G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 2002;137:75-114.
41. TABER MT, DAS S, FIBIGER HC. Cortical regulation of subcortical dopamine release: mediation via the ventral tegmental area. J Neurochem 1995;65:1407-1410.
42. KUROKI T, MELTZER HY, ICHIKAWA J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-781.
43. WISE RA, BOZARTH MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-492.
44. DI CHIARA G, IMPERATO A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-5278.
45. KOOB GF, GOEDERS NE. Neuroanatomical substrates of drug self-administration. In: COOPER SJ, LIEBERMAN JM, eds. The neuropharmacological basis of reward. New York, NY: Oxford Press, 1989:214-263.
46. DI CHIARA G, NORTH RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992;13:185-193.
47. VETULANI J. Drug addiction. Part II. Neurobiology of addiction. Pol J Pharmacol 2001;53:303-317.
48. DI CHIARA G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 1998;12:54-67.
49. JOG M, KUBOTA Y, CONNOLLY C et al. Building neural representations of habits. Science 1999;286:1745-1749.
50. WILKINSON LS, HUMBY T, KILLCROSS AS et al. Dissociations in dopamine release in medial prefrontal cortex and ventral striatum during the acquisition and extinction of classical aversive conditioning in the rat. Eur J Neurosci 1998;10:1019-1026.
51. VOLKOW ND, WANG GJ, FOWLER JS et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999;156:1440-1443.
52. ROCHA BA, FUMAGALLI F, GAINETDINOV RR et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1998;1:132-137.
53. SCHARFETTER C. General psychopathology: an introduction. Cambridge: Cambridge University Press, 1980.
54. VORUGANTI LP, AWAD AG. Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatr Scand 2005;111(suppl. 427):22-28.
55. NABER D, KAROW A, LAMBERT M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005;111(suppl. 427):29-34.
56. MARDER SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 2005;111(suppl. 427):43-46.
57. FIBIGER HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 1984;11(suppl. 1):105-107.
58. ARNT J. Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relations to effects on reward system? Psychopharmacology 1996;124:117-125.
59. ACQUAS E, CARBONI E, LEONE P, DI CHIARA G. Sch 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? Psychopharmacology (Berl.) 1989;99:151-155.
60. BERRIDGE KC, ROBINSON TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998;28:309-369.
61. WISE RA. Dopamine motivation and learning. Nat Rev Neurosci 2004;5:1-12.
62. HEINZ A. Anhedonia - a general nosology surmounting correlate of a dysfunctional dopaminergic reward system? Nervenarzt 1999;70:391-398.